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Drug designa b s t r a c t
Metallo-b-lactamases are the latest resistance mechanism of pathogenic and opportunistic bacteria
against carbapenems, considered as last resort drugs. The worldwide spread of genes coding for
these enzymes, together with the lack of a clinically useful inhibitor, have raised a sign of alarm.
Inhibitor design has been mostly impeded by the structural diversity of these enzymes. Here we pro-
vide a critical review of mechanistic studies of the three known subclasses of metallo-b-lactamases,
analyzed at the light of structural and mutagenesis investigations. We propose that these enzymes
present a modular structure in their active sites that can be dissected into two halves: one providing
the attacking nucleophile, and the second one stabilizing a negatively charged reaction intermedi-
ate. These are common mechanistic elements in all metallo-b-lactamases. Nucleophile activation
does not necessarily requires a Zn(II) ion, but a Zn(II) center is essential for stabilization of the anio-
nic intermediate. Design of a common inhibitor could be therefore approached based in these con-
vergent mechanistic features despite the structural differences.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
b-Lactam antibiotics remain the most useful chemotherapeutic
agents in the fight against bacterial infections. These antibiotics
work by inhibiting penicillin-binding proteins (PBPs) implicated
in bacterial cell wall biosynthesis, eventually causing cell lysis
[1]. The clinical success of the first b-lactam in the 1950s, penicillin
G (benzylpenicillin) led to the evolution of different resistance
mechanisms [2,3]. Increasing reports of resistance events
prompted the search and development of related compounds with
better and broader bactericidal action, giving rise to four types of
b-lactam antibiotics in clinical use today: penicillins, cephalospor-
ins, monobactams and carbapenems [4–6]. Despite much progress
in antibiotic design, resistance to b-lactams is now a serious clini-
cal problem, particularly in postsurgery, nosocomial infections and
immunosuppressed patients [7,8].
The rapid advance of resistance has dampened the interest of
pharmaceutical companies in investing in infectious diseases, lead-ing to a substantial drop in the number of new antibiotics
approved in the last years [9]. At present, there are very few new
b-lactams in the pipeline and no new classes of antibiotics directed
toward new targets available or in the pipeline [10]. Therefore, it is
mandatory in the short term to find tools extending the useful life
of available antibiotics [11].
1.1. Resistance mediated by b-lactamase enzymes
The most prevalent mechanism of resistance toward b-lactams
is the expression of enzymes able to hydrolyze these antibiotics,
namely b-lactamases. These enzymes catalyze the hydrolysis of
the b-lactam ring characteristic of these antibiotics, rendering
them inactive [1]. Most b-lactamases are known as serine-
b-lactamases (SBLs) since they possess an essential Ser residue in
their active site. These enzymes are evolutionarily related to peni-
cillin binding proteins (PBPs) and have been grouped into three
classes (A, C, and D) based on amino acid sequence alignments
[1]. Metallo-b-lactamases (MBLs, or class B) are metalloenzymes
with Zn(II) ions bound to the active site that are essential for their
activity [12,13]. MBLs have an unusually broad substrate spectrum,
being capable of hydrolyzing all classes of bicyclic b-lactam antibi-
otics (penicillins, cephalosporins and carbapenems). Though MBLs
are not capable of recognizing and inactivating monobactams
(monocyclic b-lactams), they are usually co-expressed with SBLs
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are not a plausible choice for the treatment of infections associated
with MBLs production [12].
The inhibitors (clavulanic acid, tazobactam, and sulbactam) that
are currently used in clinical settings in combination therapies
with b-lactam antibiotics are mechanism-based inhibitors of SBLs
[14]. The mechanistic differences with SBLs render MBLs resilient
to inhibition by these compounds. The rational design of
mechanism-based inhibitors against MBLs has been thwarted by
the difficulty of finding common mechanistic features among dif-
ferent MBLs and for the different substrates, as we will discuss over
this review [13].
In this sense, an understanding of the mechanism of MBLs, and
in particular the entrapment and characterization of reaction inter-
mediates, can give new hints on the structure of compounds that
might bind to the active site and inhibit these enzymes. Such com-
pounds might be used in combination with the existing b-lactam
antibiotics prolonging their use to treat resistant bacteria.
1.2. Emergence of antibiotic resistance by metallo-b-lactamases
MBLs emerged in the last two decades as the major mechanism
of resistance against carbapenems, last resort b-lactam antibiotics
for the treatment of infections caused by multiresistant pathogens
[12]. Surprisingly, the first MBL (BcII from Bacillus cereus) was dis-
covered by Sabath and Abraham in 1966, two decades before the
clinical implementation of carbapenems. These authors showed
that the cephalosporinase activity displayed by this strain could
be inhibited by treatment with EDTA [15]. This wide-spectrum
enzyme was initially considered a biochemical curiosity since it
was found in a soil bacteria, being the only example of its kind
along two decades. Notwithstanding, BcII became one of the work-
horses for structural and mechanistic studies on MBLs [16–24].
This scenario changed in the 1980s when an increasingly large
number of clinical isolates of Bacteroides fragilis [25], Stenotropho-
monas maltophilia [26], various Aeromonas [27,28] and Chryseobac-
terium [29–31] species were found to express diverse
chromosomally encoded Zn(II) b-lactamases. Among Gram nega-
tive bacteria, a silent gene coding for an MBL was found in Bacillus
anthracis [32]. The situation became more worrisome when genes
coding for MBLs were found in mobile genetic elements (which
also harbor other resistance cassettes) in several Gram negative
pathogens including members of the Enterobacteriaceae species,
Pseudomonas aeruginosa, Serratia marcescens and the Acinetobacter
species [8,12]. The association of MBL genes to these mobile
genetic elements has facilitated the dissemination of these
enzymes among prevalent pathogens, thus becoming a serious
clinical threat. Outbreaks of pathogens producing the MBLs VIM-
2 (Verona Integron-encoded Metallo-b-lactamase) and NDM-1
(New Delhi Metallo-b-lactamase) are rising in incidence all over
the world, with high rates of death due to the lack of therapeutic
options [33,34].
MBLs from environmental bacteria, initially considered as a
mere curiosity, are now considered gene reservoirs which may
be later transferred to opportunistic and pathogenic strains
[35–37]. Recent studies revealed the presence of a wide variety
of NDM-1-producing pathogens in public drinking water taps
and seepages from New Delhi [38], revealing that the transmission
of this gene has surpassed hospital barriers.
1.3. MBLs superfamily and classification
MBLs constitute a family of proteins belonging to an ancestral
superfamily of metallohydrolases, all of them sharing a
common ab/ba sandwich scaffold and a metal-binding motif (His/
Asn116-X-His118-X-Asp120-His/Arg121, His196, Cys/Ser221, His263,according to the standard BBL numbering scheme [39]) located in
the interface of the two ab domains [40]. Members of this super-
family display a wide variety of activities, including human glyox-
alase II, phosphodiesterase from Escherichia coli, parathion
hydrolase from Pseudomonas sp., N-acyl homoserine lactone
hydrolase de Bacillus thuringiensis and a human DNA nuclease;
and a group of cytosolic redox proteins, among others [40]. Most
of the non-b-lactamase hydrolases present dinuclear sites contain-
ing Zn(II), Fe(II)/Fe(III) or Mn(II) ions, with an Asp/Glu221 residue as
a bridging ligand between the two metals. On the other side, MBLs
lack a bridging protein residue; instead a water/hydroxide mole-
cule occupies the bridging position while at position 221 a Cys or
Ser residue is present [40].
The family of MBLs is divergent, with sequence identities as low
as 10% or less in some cases. Even though, a classification in sub-
classes was performed based on sequence alignment guided by
common structural features [39]. Subclass B1 and B3 MBLs are
di-Zn(II) enzymes with a broad substrate profile (penicillins,
cephalosporins and carbapenems) [41–45]. The smaller subgroup
B2, albeit phylogenetically closer to B1 enzymes [46], includes
mono-Zn(II) enzymes capable of hydrolyzing exclusively carbapen-
ems [47]. Subclass B1 enzymes exhibit sequence identities higher
than 23% between their members [40]. This group includes almost
all the clinically relevant MBLs: the aforementioned NDM [48] and
VIM variants [49], in addition to IMP (Imipenemase) variants [50]
SPM-1 (São Paulo Metallo-b-Lactamase) [51], acquired by patho-
gens through mobile genetic elements, apart from other endoge-
nous MBLs like chromosome-borne B. cereus BcII [52], B. fragilis
CcrA [53] or Elizabethkingia meningoseptica BlaB (b-lactamase B)
[29]. The exclusive carbapenemases from subclass B2 share 11%
sequence identity with B1 enzymes [40]. This group includes
endogenous MBLs like A. hydrophilia CphA (Carbapenem-
hydrolyzing metallo-b-lactamase) [54], Aeromonas veronii ImiS
(Imipenemase from A. veronii bv. sobria) [28] and Serratia fonticola
Sfh-I [36]. Finally, subclass B3 MBLs, the most distant in phyloge-
netic terms [46], comprises endogenous enzymes sharing only 9
residues with the rest of MBLs. Members of this group include
chromosome-borne MBLs S. maltophilia L1 [26], E. meningoseptica
GOB [30] and Legionella (Fluoribacter) gormannii FEZ-1 [55]. The
recently reported AIM-1 (Australian Imipenemase) represents the
first B3 enzyme encoded in a mobile genetic element, suggesting
that gene dissemination may not be limited to subclass B1 [56].
1.4. Active site structure of metallo-b-lactamases
The crystal structures of B1 and B3 enzymes have revealed din-
uclear metal centers in the active site, comprised of two Zn(II) ions:
one in a tetrahedral coordination sphere (Zn1 or M1 site) and one
in a trigonal bipyramidal coordination sphere (Zn2 or M2 site)
[18,42,43,57–59]. In B1 enzymes, the Zn(II) ion at the M1 site is
coordinated to residues His116, His118 and His196 and a bridging
water/hydroxide molecule (Wat1); while the Zn(II) ion at the M2
site is coordinated to residues Asp120, Cys221 and His263, the
bridging water and an apical water molecule (Wat2). In B3
enzymes, the arrangement of the Zn2 site is modified with respect
to B1 enzymes. These enzymes present a Ser residue at position
221 that does not participate in metal coordination. Instead, a
His residue at position 121 completes the coordination sphere of
the Zn2 site. Mutational analyses on B1 enzymes have shown that
all metal binding residues are essential to provide full activity [19].
According to substrate binding experiments performed with BcII,
the apo-enzyme is not able to bind b-lactam substrates, indicating
that substrate binding in B1 MBLs is largely driven by electrostatic
interactions with the metal ions [20]. Particularly, the interaction
of the invariant b-lactam carboxylate moiety (at C3 in penicillins
and carbapenems and C4 in cephalosporins) with Zn2 has been
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duct (EP) complexes of MBLs representative of the three sub-
classes, as we will discuss later [59–61]. This carboxylate moiety
also interacts with a highly conserved charged residue at position
224 in B1 and B2 enzymes and residues Ser221 and Ser223 in B3
enzymes [59–61].
B2 enzymes are fully active with a single Zn(II) ion localized in
the M2 site, sharing the same ligand residues as in B1 enzymes, i.e.,
Asp120, Cys221 and His263 [47,62]. A naturally-occurring
His116Asn substitution at the M1 site precludes Zn(II) from bind-
ing with high affinity, while in the presence of excess Zn(II), bind-
ing to this site can be inhibitory [47]. A mutational analysis of the
B2 enzyme CphA, showed that metal ligands Asp120, Cys221 and
His263 are essential for the enzyme activity, as well as residues
His118 and 196 [63].
The presence of residue Cys221 in B1 and B2 MBLs contrasts
with the ubiquity of a Asp/Glu221 bridging ligand in other mem-
bers of the MBL superfamily devoid of lactamase activity. The
Cys ligand (despite being absent in B3 enzymes) is a hallmark of
the active site of MBLs, since Cys residues are rarely found as Zn
(II) ligands in exposed catalytic sites [64]. This is most striking con-
sidering that MBLs bind the Zn(II) cofactor in the oxidizing
periplasmic space. The observation that B3 enzymes, lacking a
Cys ligand, are phylogenetically closer to other members of the
MBL superfamily [40] suggests that this residue confers an evolu-
tionary advantage. Indeed, we recently demonstrated that a Cys
residue in the metallic centers of B1 MBLs is critical for ensuring
metal uptake in the periplasmic space of Gram-negative bacteria,
leading to the active dinuclear enzyme [24].2. Is it possible to establish a common catalytic mechanism for
all MBLs?
b-Lactam hydrolysis involves a nucleophilic attack to the car-
bonyl group, the C–N bond cleavage and the protonation of the
nitrogen. The bicyclic shape of b-lactams requires that both the
nucleophilic attack and nitrogen protonation take place on the less
hindered a side of the antibiotic molecule. So far, the central issues
discussed on the mechanism of MBL-mediated catalysis have been:
(1) whether these events occur in a concerted manner or in dis-
crete steps with accumulation of reaction intermediates, (2) the
identities of the nucleophile and the proton donor, and (3) the role
of each Zn(II) ion in catalysis. Initial mechanistic schemes were
proposed based on the well-known mechanism for b-lactam
hydrolysis by Serine-b-lactamases (Fig. 1A). In these enzymes,
the attacking nucleophile is an activated Ser residue, that gives rise
to a high energy transition state with a tetrahedral carbon (known
as ‘‘tetrahedral intermediate”), in which the anionic charge devel-
oped is stabilized by a positively charged cleft in the active site,
known as the ‘‘oxyanion hole”, by analogy to the one present in
serine proteases. Cleavage of the C–N bond of the b-lactam occurs
synchronously with protonation of the b-lactam nitrogen, resulting
in formation of a covalent acyl-enzyme intermediate (Fig. 1A).
Attack by a catalytic water leads to another high-energy transition
state. Finally, the rate-limiting deacylation step involves cleavage
of the covalent bond between the b-lactam carbonyl and the oxy-
gen of Ser70, coupled to the protonation step [14].
Mechanistic studies can make use of the classical methods:
steady state kinetics, pre-steady state kinetics, site-directed muta-
genesis and X-ray crystallography. In addition, the active site of Zn
(II) enzymes can be selectively interrogated by X-ray Absorption
Spectroscopy (XAS) and its variants, XANES and EXAFS. The
requirement of synchrotron sources makes this technique less
amenable to follow reactions in real time but, instead it has been
extensively employed to trap reaction intermediates after RapidFreeze-Quench (RFQ) of the reaction. Substitution of Zn(II) by diva-
lent metal ions that are useful spectroscopic probes (mostly Co(II))
and preserve enzyme catalytic activity, has been extensively
employed. These metal surrogates enable the use of additional
techniques such as absorption spectroscopy, EPR and NMR, either
in real time or coupled with Rapid Freeze-Quench devices.
Clinically useful b-lactam antibiotics do not possess intrinsic
chromophores, but several groups have exploited the use of syn-
thetic chromophoric cephalosporins, such as nitrocefin, CENTA
and chromacef. These compounds undergo intense spectroscopic
changes upon hydrolysis that make them useful mechanistic
probes. In this case, native Zn(II)-MBLs can be employed, but the
spectral changes only give information on changes at the substrate
molecule. Instead, Co(II) substitution allows monitoring changes
on the enzyme active site during turnover, since characteristic
bands corresponding to each metal-site can be followed in the
UV–vis region.
Computational studies are challenging since transition metal
ions are difficult to parametrize. The advent of density functional
theory (DFT) provided the bases to perform reliable quantum
mechanics (QM) and quantum mechanics–molecular mechanics
(QM–MM) hybrid calculations on metalloenzymes [65]. Through-
out this chapter we will describe how these approaches have con-
tributed to the interpretation of experimental evidence.
2.1. Mechanism of B1 and B3 metallo-b-lactamases
The dinuclear MBLs CcrA, IMP-1, BcII and NDM-1 (subclass B1)
and L1 (subclass B3) are those whose catalytic mechanisms have
been better characterized to date. We will focus our discussion
on the pre-steady state mechanistic studies, together with struc-
tural evidence from the crystallographic structures of L1 and
NDM-1 bound to hydrolyzed substrates. In addition, we will men-
tion mutational analyses to assess the role on catalysis of amino
acid residues located in the active site or in nearby loops.
2.1.1. Identities of the nucleophile and the proton donor
The two candidates proposed as the possible attacking nucle-
ophile were the carboxylate group of the conserved residue
Asp120 and the Zn(II)-bound hydroxide ion. Asp120 was early dis-
carded as the nucleophile [17,66]. At present, the general consen-
sus accepts that the Zn(II)-bound hydroxide ion is the attacking
nucleophile, as it is the case for most Zn(II) hydrolases, in which
the metal ion lowers the pKa of the bound water molecule
[67–71]. The Zn1–Wat1 distance in B1 enzymes is typically
1.9–2.0 Å long, characteristic of a Zn(II)-bound hydroxide [72];
while the Zn2–Wat1 distance varies between 2.5 and 3 Å (Table 1)
[18]. These data suggest that only Zn1 would be responsible of
lowering the pKa. However, the finding that metal dissociation
from the Zn2 site gave rise to an inactive enzyme led Page and
coworkers to propose that the second Zn(II) ion was essential for
activity [73,74]. These authors suggested that Zn2 contributes to
lowering the pKa of the attacking nucleophile. However, a hydrox-
ide moiety bridging two transition metal ions is expected to have
less nucleophilic potency than a terminal hydroxide. A crystal
structure of a BcII mutant showing that the short Zn1–Wat bond
is preserved both in its mono- and dinuclear form [24] confirmed
that the Zn2 ion is not required to provide an active nucleophile
at neutral pH, at the same time supporting the idea of an attacking
terminal hydroxide.
The identity of the proton donor is still not clear. Asp120 was
originally proposed as the proton donor, being essential for activity
in all MBL enzymes [75–79]. However, this hypothesis requires
transient dissociation of the carboxylate group from the metal
ion upon protonation [80], a fact that has not been substantiated.
The role of Asp120 as a proton donor was ruled out by a series of
Fig. 1. (A) Reaction mechanism for penicillin hydrolysis by class A serine-b-lactamases. This reaction scheme is based in the one reported in Ref. [14], which reviews original
data. (B) Reaction mechanism for penicillin hydrolysis by di-Zn(II) B1 enzymes. The reaction scheme is based on the results on penicillin G hydrolysis by di-Co(II)–BcII from
Ref. [22]. The representation of E is taken from the crystallographic structures of di-Zn(II) BcII (PDB 1BC2) and di-Co(II) BcII (PDB 3I11). The representation of EP is based on
the crystallographic structures of NDM-1 complexed with hydrolyzed penicillins (see Section 3.1). W1 stands for Wat1 and W2 stands for Wat2.
Table 1
Relevant distances in the active sites of MBLs in their free forms from X-ray crystallography.
Free forms Distance (Å)
PDB code Enzyme (subclass) Resolution (Å) References Chain Zn1–Zn2 Wat1–Zn1 Wat1–Zn2 Wat2–Zn2
3SPU NDM-1 (B1) 2.1 [123] A 3.8 2.5 2.5 2.5
B 3.9 1.9 2.6 2.7
2FM6 L1 (B3) 1.8 [58] A 3.5 1.9 1.9 2.5
B 3.5 1.8 2.1 2.5
Wat1–H118 Wat1–D120 Wat1–H196 Wat1–Zn2 Wat2–Zn2
1X8G CphA (B2) 1.7 [61] 3.1 3.4 4.4 4.0 –
3SD9 Sfh-I (B2) 1.9 [62] A 2.0 3.8 2.5 3.5 2.2
B 2.0 4.4 2.4 3.4 2.3
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kinetic isotope effect, therefore indicating that the rate-limiting
step is a proton transfer in all cases [78]. The fact that kcat is not sig-
nificantly affected in the D120N mutant, indicates that Asp120 isnot the proton donor in the rate-determining step [78]. These
results were in agreement with those obtained with mutants on
Asp120 position in the B3 MBL L1 [76]. Structural studies on
Asp120 mutants suggest that, instead, its role is to adequately
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naga and Page have shown that BcII is inactivated at low pH by
protonation of two residues, tentatively a Zn(II)-bound water
molecule and Asp120 [17]. It was later shown that this inactivation
at acidic pH is due to Zn(II) dissociation [82,83], as a consequence
of protonation of Asp120. Based on this evidence, it seems unlikely
that Asp120 might detach from the metal ion to be involved in a
proton relay. An alternative proton donor candidate could be the
carboxylic acid moiety formed upon b-lactam cleavage [59].
Instead, the most accepted hypothesis is that of a water molecule
being the proton donor. These proposals will be analyzed in detail
later.
2.1.2. Mechanistic studies on penicillin G hydrolysis using Co(II)-
substituted enzymes
The substitution of the native Zn(II) ion by Co(II) in B1 MBLs
gives rise to a characteristic UV–vis spectrum with a pattern of
ligand field bands in the region between 500 and 650 nm, which
present contributions of the metal ions in both sites, and a
ligand-to-metal charge-transfer band (LMCT) around 340 nm cor-
responding to Cys? Co(II) bond from the Zn2 site [84–86]. The
coordination number and geometry of the metal sites can thus
be determined based on the electronic spectrum of the Co(II)-
substituted enzymes both in the resting state and during turnover.
In addition, Co(II)-substituted MBLs are slightly less active than the
native Zn(II) variants, making them more amenable for trapping
catalytic intermediates.
Mechanistic studies employing rapid-scanning stopped-flow
techniques allow monitoring the spectral changes during turnover
which are indicative of changes of the coordination sphere of the
Co(II) ion during the reaction. Bicknell and Waley performed
pioneering mechanistic studies on Co(II)-substituted BcII [16,87].
The authors documented the presence of two different enzyme–
substrate (ES) complexes upon hydrolysis of penicillin G by follow-
ing the reaction by means of electronic and MCD spectroscopy. A
branched kinetic mechanism accounted for the observed kinetic
data and ES complexes. These experiments were performed before
the active site structure of these enzymes was known, and the
results were interpreted by assuming a single Co(II) at the active
site. Despite this fact, this work provided the first evidences of
changes in the coordination geometry of the metal ions in the
active site during turnover.
Steady state studies on the hydrolysis of penicillin G by Co(II)–
BcII show a biphasic behavior, with an initial burst followed by a
steady state rate [73]. Page and co-workers assigned the first burst
to penicillin hydrolysis by di-Co(II) BcII, while the decrease
observed in the reaction rate was attributed to the dissociation
of one of the Co(II) ions during turnover, giving rise to a less active
or inactive mono-Co(II) form. These experiments were carried out
following the spectral changes on the substrate, without monitor-
ing the structural features of the enzyme active site.
We later reported a pre-steady state kinetics study aimed at
addressing the activity of the different metal-loaded species of BcII
[22]. Hydrolysis of penicillin G catalyzed by BcII samples with dif-
ferent Co(II)/BcII ratios was followed using a stopped-flow system
associated to a photodiode array detector (PDA), considering the
relative populations of the different species [84]. The kinetic data
were better described by a branched kinetic pathway with two
active species: di-Co(II) BcII and mono-Co(II) BcII. This model can
also explain the biphasic progress curves previously observed by
Page and coworkers [73], without assuming an inactive mono-Co
(II) enzyme, as a result of re-equilibration of mono and di-Co(II)
species after dilution on the reaction mix.
In the resting state, mono-Co(II) BcII is a mixture of a mono-Co
(II) form at the M1 site and mono-Co(II) species at the M2 site in
equilibrium [84]. The kinetic data on BcII is consistent with amono-Co(II) active species with the metal ion localized in M2 site,
although experimental studies on hydrolysis of cephalosporins by
mono-Zn1 Bla2 [88], mono-Zn1 L1 [89] and calculations on mono-
Zn1 BcII [90] support the existence of an active mono-Zn1 form. In
the mono-Co(II)-M2 enzyme, the attacking nucleophile would be a
water molecule activated by interactions with His118 and/or
Asp120, similar to the mechanism proposed for mononuclear B2
enzymes [61,62], as we will discuss later.
No reaction intermediates could be trapped in penicillin hydrol-
ysis by BcII, and the branched mechanism reported by Bicknell and
Waley [16] could be assigned to the dinuclear enzyme. Structures
were proposed for the two ES complexes based on the spectro-
scopic data [22]. The interactions proposed for ES1 complex are
in agreement with those observed in the enzyme–product (EP)
complexes of penicillins and NDM-1 enzyme [44,59], while the
interactions proposed for ES2 account for the increase in coordina-
tion number of Co(II) as indicated by the spectroscopic data [22].
(Fig. 1B) [22].
2.1.3. Mechanistic studies with cephalosporins
In 1998, Benkovic and coworkers reported that nitrocefin
hydrolysis by the di-Zn(II) B1 enzyme CcrA proceeded with accu-
mulation of a reaction intermediate with a strong absorption fea-
ture at 665 nm [66,91]. This band was attributed to an anionic
enzyme-bound intermediate with a negatively charged nitrogen
atom upon scission of the b-lactam C–N bond (EI, Fig. 2A). The
spectrum of this intermediate was reproduced by treating hydro-
lyzed nitrocefin with a strong base, strongly supporting this pro-
posal [66]. Nitrocefin and chromacef hydrolysis by the di-Zn(II)
B1 enzyme NDM-1 also take place with the accumulation of a sim-
ilar intermediate [92]. This intermediate was also reported in
nitrocefin hydrolysis by the B3 enzyme L1 [93]. RFQ-EPR of Co
(II)-substituted L1 demonstrated that nitrocefin binding results in
a change in the geometry of the Co(II) ions, providing evidence that
the reaction intermediate is a metal-bound species [94]. RFQ-XAS
on di-Zn(II) L1 also evidenced a significant lengthening of the
Zn–Zn distance in this intermediate (from 3.42 in the resting state
to 3.72 Å) [95]. QM/MM calculations [96] and model studies [97]
supported the anionic structure of this intermediate, which fea-
tures Zn2 bound to the negatively charged b-lactam nitrogen. This
mechanism provided the first direct evidence of a catalytic role for
the M2 site.
The rate-limiting step in this reaction is the decay of this inter-
mediate, characterized by a solvent kinetic isotope effect of 2.9,
consistent with the assignment of this decay to the protonation
of the ring-opened nitrogen anion [91,98] (Fig. 2A, EI? EP). This
brings us back to the issue of the identity of the proton donor. As
mentioned in Section 2.1.1, the most accepted hypothesis postu-
lates a water molecule as the proton donor. One possibility is that
an incoming water molecule from the bulk solvent is acidified by
coordination to either one or both Zn(II) ions, hence providing
the proton required to protonate the b-lactam nitrogen, regenerat-
ing the bridging nucleophile hydroxide [89]. However, it is not
likely that water molecules can reach the active site once a sub-
strate molecule is bound. Alternatively (Fig. 2A), we propose that
the proton donor is a water molecule bound to Zn2 in the resting
state enzyme (W2) that shifts toward Zn1, replacing the vacant
position left by the nucleophilic OH. This water molecule, bridg-
ing Zn1 and Zn2 in EI, is expected to have a low pKa, thus facilitat-
ing nitrogen protonation in an event which regenerates the
nucleophilic hydroxide in EP. As shown in Figs. 1 and 2, Asp120
can orient the bridging water to donate a proton to the intermedi-
ate. RFQ-EPR studies on the hydrolysis of chromacef by metal sub-
stituted NDM-1 with Co(II) in the M1 site (CoCd-NDM-1) also
showed that the M1 site undergoes a marked change in electronic
structure upon reaction with substrate, indicative of a decrease in
Fig. 2. (A) Reaction mechanism for nitrocefin hydrolysis by di-Zn(II) B1 and B3 enzymes. EI is the experimentally characterized anionic intermediate interacting with Zn2 via
the N atom and the carboxylate [66,91]. The same scheme would be valid for other chromogenic cephalosporins such as cromaceph and CENTA [92]. (B) Reaction mechanism
for imipenem hydrolysis by di-Zn(II) B1 and B3 enzymes. EI1 and EI2 are the experimentally characterized anionic intermediates [23], stabilized by interaction with Zn2. The
representation of EI2 is based on the crystallographic structures of NDM-1 in complex with hydrolyzed meropenem (PDB 4EYL, see Fig. 4) [44]. W1 stands for Wat1 and W2
stands for Wat2.
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results were interpreted as a five-coordinate Co(II) in the M1 site in
EI, which could be attributed to simultaneous coordination of both
O atoms from the newly formed carboxylate of the ring-opened
intermediate (one from the l-OH ligand, one from the substrate
carbonyl; as proposed for ES2 in Fig. 1B for penicillin-hydrolysis),
or by coordination of a water molecule. These observations suggest
a role for the metal ion in the M1 site in nucleophile activation and/
or delivery of the proton donor [86].The p-conjugated electron-withdrawing substituent in nitro-
cefin stabilizes this anionic intermediate. Instead, the pKa of the
ring nitrogen in hydrolysis products of penicillins and clinically rel-
evant cephalosporins is expected to be much higher, suggesting
that analogous intermediates are not to be expected for these sub-
strates. However, DFT calculations on the mechanism of cefo-
taxime hydrolysis by di-Zn(II) CcrA [99] suggest that a Zn(II) ion
in the M2 site would favor stabilization of a negative N5 atom upon
nucleophilic attack and scission of the C–N bond. Steady state
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tope effect for kcat was 1.4–1.6 for penicillin, cefuroxime, cephalor-
idine, and cefotaxime, suggesting that the rate-limiting step also
involves proton transfer for these substrates [17,84]. These smaller
values can be interpreted as reflecting the contribution of a metal-
bound hydroxide (with an expected solvent effect of 0.7–0.8)
together with proton transfer (with a solvent effect of 2.5–3.0)
[100]. However, since these values correspond to steady state
parameters, it is not possible to discard the existence of an anionic
intermediate for these substrates only based on these data.
The role of the M2 site in this mechanism was confirmed by
studying mono-Zn(II) variants. A mono-Co(II) L1 variant with the
metal ion localized at the M2 site resulted inactive, while the
mono-Zn(II) at M2 site analog could not be obtained [89]. On the
other hand, mono-Zn(II) GOB is an active enzyme with the metal
ion localized at the M2 site and displays a marked accumulation
of this intermediate [101]. Spectroscopic data from hydrolysis of
chromacef by heterodimetallic forms of NDM-1 provided evidence
of the binding of a moiety capable of absorbing delocalized spin
density from the metal ion at the M2 site and a major role for
Zn2 in electrophilic activation of the substrate and stabilization
of the anionic intermediate [86].
Studies aimed at determining the role of the metal in the M1
site rely on pre-steady state studies under single-turnover condi-
tions, since the existence of the mono-Zn(II) enzyme under
steady-state conditions cannot be assured due to the metal con-
centration in Chelex-treated buffers. Unlike mono-Zn(II) enzymes
with the metal localized at the M2 site, the mono-Zn1 forms of
B1 and B3 enzymes do not stabilize the anionic intermediate.
Pre-steady state studies with a mono-Zn(II) form of L1, with the
metal ion localized at the M1 site, presented low activity against
nitrocefin (5% of the activity of di-Zn(II) L1), and did not stabilize
the hydrolysis intermediate [89]. The B1 MBL Bla2 from B. anthracis
was purified with one Zn equivalent, localized at the Zn1 site
according to EXAFS studies [88]. This protein preparation pre-
sented the peculiarity of being unstable when trying to saturate
with Zn(II), precluding a comparative stopped-flow study on the
di-Zn(II) enzyme. Mono-Zn1 Bla2 did not show accumulation of
the nitrocefin intermediate, though it presented a considerable
activity. Spectroscopic data on Bla2 indicates that Co(II) binds to
the two sites with no preference, as is the case for BcII. An enzyme
analog with 1 or 2 equiv. of Co(II) added accumulated the anionic
intermediate. Based on the amount of the intermediate observed,
the authors propose an equilibrium shift toward the di-Co(II)
enzyme in the presence of substrate.
Hybrid Car–Parrinello QM/MM calculations were used to inves-
tigate the reaction mechanism of hydrolysis of cefotaxime by
mono-Zn1 BcII [90]. The Zn1-bound water/hydroxyl is the attack-
ing nucleophile and the calculations show that a second water
molecule binds the zinc ion in the first step of the reaction, expand-
ing the zinc coordination number and providing a proton donor
adequately oriented for the second step. Asp120, Cys221, and
His263 (which are ligands of Zn2 in the dinuclear enzyme) partic-
ipate in a conserved hydrogen bond network in the active site,
which initially contributes to orient the nucleophile, and then
guides the second catalytic water molecule to the zinc ion after
the substrate is bound. Cleavage of the b-lactam C–N bond occurs
concomitantly with protonation of N5. The activation energy for
the mechanism catalyzed by the mono-Zn(II) variant [90] was
much higher than calculated for the di-Zn(II) enzyme [99], in
agreement with the experiments showing that the active species
in vivo is the dinuclear one [24].
This intermediate, however, can be elusive in some dinuclear
enzymes: no accumulation or little was reported for BcII [102] or
VIM-2 [85], while there are contradicting results for nitrocefin
hydrolysis by IMP-1 by the Frère [103] and Crowder groups[104]. A second sphere mutation introducing a hydrogen bond
with a metal ligand in BcII leads to stabilization of this intermedi-
ate, which is not observed in the native enzyme [105], disclosing
that subtle changes between different MBLs also contribute to
the stability of this EI species.
The accumulation of this intermediate is also affected by the
dynamic of loops flanking the active site. Loop dynamics in MBLs
has been probed by NMR [106–109], fluorescence of engineered
Trp residues [110], or double electron resonance (DEER) spec-
troscopy in spin-labeled samples [111,112]. Loop L3 is a short,
mobile loop present in B1 enzymes (residues 56–66) that closes
over the active site upon substrate binding, affecting catalysis
[106–109]. Insertion of the B3 loop from IMP-1 into BcII resulted
in accumulation of the intermediate [103]. A natural mutation in
loop L10 (residues 220–237) in the allelic variant IMP-25 also leads
to a more populated intermediate than in IMP-1. In the case of B3
enzymes, a study of mutations in loop L8 (residues 151–166)
showed that loop motions correlated with the rate of formation
of the nitrocefin intermediate [110]. Overall, these results demon-
strate that, in addition to the presence of the Zn(II) ion at the M2
site, several additional factors contribute to the relative stabiliza-
tion of this anionic intermediate.
2.1.4. Mechanistic studies with carbapenems
The mechanism of carbapenem hydrolysis, despite being the
paradigmatic substrate of MBLs, has been less studied. Pre-steady
state studies on imipenem hydrolysis by di-Zn(II) BcII revealed for-
mation of a reaction intermediate absorbing at 380 nm. Co(II)-
substitution allowed a more detailed characterization of this pro-
cess. Di-Co(II) BcII hydrolyzes imipenem by a branched mechanism
with accumulation of two reaction intermediates, one of themwith
a strong absorption at 407 nm [23]. RFQ-Resonance Raman exper-
iments allowed assigning this band to a deprotonated form of a
ring-opened pyrrolidine derivative (EI1 in Fig. 2B), which resembles
the anionic intermediate identified in nitrocefin hydrolysis. The
difference in the position of the absorption maxima when the reac-
tion is performed with Co(II) or Zn(II)BcII confirms the direct
involvement of the metal ion in this intermediate.
Carbapenem hydrolysis is usually followed by tautomerization
of the pyrrolidine double bond from D1 to D2 [113,114]. Both Zn
(II)–BcII and Co(II)–BcII give rise to a D1 product with a 7:3 dias-
teromeric ratio, which suggests a stereoselective protonation of
the carbanionic species at C3 [23]. The proposed branched reaction
mechanism includes two intermediates, EI1 and EI2 (Fig. 2B). The
nucleophilic attack gives rise to an open-ring derivative with a
negative charge delocalized over a conjugated p system involving
atoms N1 and C3. This anionic species (EI1) is stabilized by direct
interaction with Zn2. EI1 can: (a) be protonated at N1 giving tau-
tomer D2, that once released to the aqueous milieu tautomerizes
rapidly to its D1 form giving a mixture of the a and b diasteromers;
or (b) remain inside the enzyme pocket, favoring localization of the
negative charge on C3 (EI2). In the latter case, EI2 could be proto-
nated stereospecifically by a metal-bound water giving rise to an
enzyme–product adduct (EI3 or EP). This model accounts for the
partial stereoselectivity.
DFT calculations showed that a stable intermediate species can
be stabilized at the active site, with a delocalized negative charge
encompassing the N1 and C3 atoms of the pyrrolidine ring and
the Sulphur atom of the R2 substituent [23]. Recent QM–MM cal-
culations on the reaction coordinate of hydrolysis of meropenem
by NDM-1 by Nair and coworkers support formation of a stable
anionic intermediate species [115].
A similar intermediate was recently reported in the hydrolysis
of meropenem by di-Zn(II) SPM-1 [116]. Regarding mono-
metallic variants, this intermediate has been show to accumulate
in mono-Co(II) BcII with the metal at the Zn2 site [23]. Instead, a
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resulted in a loss of the enzyme activity due to the inability to sta-
bilize this intermediate, definitively proving the essentiality of the
Zn2 site in catalysis [24].
2.2. Mechanism of B2 metallo-b-lactamases
B2 MBLs are efficient carbapenemases, with poor activity
against penicillins and cephalosporins [117–119]. These enzymes
(CphA, ImiS and Sfh-I) show their maximum activity in the
mono-Zn(II) form, while binding of a second Zn(II) ion inhibits
them to different degrees depending on their metal binding affini-
ties (see below). The crystal structures of CphA and Sfh-I revealed
that the tightly bound Zn(II) ion is located on the M2 site [61,62].
Another distinctive feature of these structures is the presence of an
a-helix on the edge of the active site groove and a group of
hydrophobic residues that, together with this helix, define a
hydrophobic wall on the active site [61,62], in contrast with the
flexible loops present in B1 and B3 enzymes.
2.2.1. Mechanistic studies on B2 enzymes
Extensive mechanistic studies are available for the hydrolysis of
imipenem and meropenem catalyzed by ImiS [120]. The activity of
ImiS is not affected by pH in the 5.0–8.5 pH range, while proton
inventories indicated at least one rate-limiting proton transfer,
with a solvent kinetic effect of 1.7. Stopped-flow fluorescence stud-
ies on ImiS, which monitor changes in tryptophan fluorescence on
the enzyme upon substrate binding, displayed biphasic time
courses upon reaction with imipenem and meropenem, with the
second, slower phase corresponding to substrate hydrolysis and
product release, which could not be distinguished. Mechanistic
studies on Co(II)-substituted ImiS showed no changes in the
absorption spectrum of the metal site during turnover, despite
RFQ-EPR studies supported accumulation of a reaction intermedi-
ate with a five-coordinate metal center. Unpublished pre-steady-
state experiments from our group on the hydrolysis of imipenem
by Zn(II)-Sfh-I disclosed the existence of transiently populated
intermediates during the catalytic cycle, similar to the one
reported for the reaction catalyzed by di-Zn(II) BcII (Fig. 2B).
Despite there might be differences between the distinct B2
enzymes, it is clear that carbapenem hydrolysis takes place by a
reaction intermediate involving changes in the geometry of the
only metal site present in these enzymes, i.e., the Zn2 site.
The crystal structure of Sfh-I at 1.33 Å allowed elucidating the
arrangement of water molecules in the active site [62]. In this
structure, the coordination sphere of Zn2 is completed by a singleFig. 3. Minimum reaction mechanism for carbapenem hydrolysis by mono-Zn(II)-B2
structures of CphA, free and in complex with hydrolyzed biapenem [47,61], and of the fwater molecule, with a Zn2–Wat2 distance (2.24 Å; Table 1) con-
sistent with a water molecule rather than with a hydroxide. The
Zn1 site is occupied by a second water molecule (Wat1), involved
in a hydrogen bond network, with a particularly strong interaction
with His118 (O-Nd1 2.0 Å) that suggests water activation by this
His residue, despite involvement of Asp120 cannot be discarded
[61].
The Zn(II) ion steers substrate binding to the carboxylate group,
aided by a positively charged residue in position 224, conserved in
B2 enzymes. Wat1 is thus expected to be the attacking nucleophile
(Fig. 3), resulting in the opening of the b-lactam ring to form an
anionic intermediate [62], analogous to the mechanism proposed
for dinuclear enzymes (Fig. 2B). Protonation of this intermediate
can occur on N1 (in a buried, less accessible position) or on C3, giv-
ing rise to different tautomers. Impaired proton transfer in B2
MBLs implies that the anionic intermediate can accumulate during
carbapenem hydrolysis, as is the case in the B1 and B3 enzymes.
This is consistent with the spectroscopic features of the intermedi-
ate observed using stopped-flow coupled to a PDA detector in Sfh-I
(unpublished results from our group). This intermediate can also
be related to the one found on imipenem hydrolysis by ImiS using
rapid-freeze quench EPR [120].
In summary, the main mechanistic difference of B2 enzymes
with the dinuclear B1 and B3 MBLs is the fact that the metal ion
is not involved in the activation of the water nucleophile. However,
the twofold role of Zn(II) in B2 enzymes in binding the substrate
and stabilizing the anionic intermediate resembles the role pro-
posed for the Zn2 site in B1 and B3 enzymes, despite the different
active site topologies and metal site content.
2.2.2. The inhibitory site of B2 enzymes
The His116Asn change in B2 MBLs abolishes productive binding
of Zn(II) at the M1 site, removing a conserved His ligand in B1 and
B3 enzymes. All B2 enzymes bind a second Zn(II) equivalent, with
dissociation constants ranging from a surprisingly low value of 15
nM in ImiS [118] to 40–90 lM in CphA [117] and Sfh-I [119]. The
effect of the second Zn(II) equivalent in the carbapenem activity
is also different, showing inhibition in CphA and ImiS, and no effect
for Sfh-I.
The structure of di-Zn(II) CphA showed that the second inhibi-
tory Zn(II) ion binds to a slightly modified M1 site, through coordi-
nation to His196 and His118 [47]. From this structure it was
proposed that binding of the second Zn(II) ion to His118 and
His196 would prevent them from playing a key role in the hydrol-
ysis of carbapenems catalyzed by B2 MBLs. This coordination
geometry is consistent with the inhibition at lM Zn(II) observedenzymes. The arrangement of water molecules is based on the crystallographic
ree form of Sfh-I [62]. W1 stands for Wat1 and W2 stands for Wat2.
Table 2
Relevant distances in the active sites of MBLs in EPa or EIb complexes from X-ray crystallography.









1.3 Ampicillin [59] A 4.6 2.1 3.0 – 2.4 4.3 2.2 2.2
B 4.6 2.0 3.0 – 2.5 4.3 2.2 2.2
4EYF NDM-1a
(B1)
1.8 Penicillin G [44] A 4.6 1.9 3.1 – 2.5 4.4 2.2 2.2
B 4.6 2.0 3.1 – 2.4 4.4 2.1 2.2
4EY2 NDM-1a
(B1)
1.2 Methicillin [44] A 4.6 2.0 3.0 – 2.5 4.4 2.2 2.1
B 4.6 2.0 3.0 – 2.5 4.4 2.2 2.2
4EYB NDM-1a
(B1)
1.2 Oxacillin [44] A 4.5 2.0 2.9 – 2.5 4.4 2.2 2.1
B 4.6 2.0 3.0 – 2.5 4.4 2.1 2.1




References Chain Zn1–Zn2 Wat1–Zn1 Wat1–Zn2 Wat2–Zn2 C8O–Zn1 C8O–Zn2 C4O–Zn2 N5–Zn2
Cephalosporins
2AIO L1 (B3)a 1.7 Moxalactam [60] 3.7 2.0 2.2 – 2.4 4.2 2.3 2.4
4RL0 NDM-1b
(B1)
1.3 Cefuroxime [79] A 3.8 2.0 2.2 – 2.8 4.2 2.1 2.4
B 3.8 2.0 2.2 – 2.9 4.2 2.2 2.3
4RL2 NDM-1a
(B1)
2.0 Cephalexin [79] A 4.5 1.8 3.0 – 2.5 4.3 2.3 2.4
B 4.5 2.0 2.8 – 2.4 4.3 2.3 2.4










1.9 Meropenem [44] A 4.0 – – – 2.3 2.5 3.0 2.2
B 3.9 – – – 2.2 2.7 2.9 2.3
4RBS NDM-1a
(B1)
2.4 Meropenem To be
published
(Kim, et al.)
A 4.0 – – – 2.0 3.3 3.0 2.1
B 4.0 – – – 2.2 3.0 3.1 2.1
Wat1–H118 Wat1–D120 Wat1–H196 Wat1–Zn2 Wat2–Zn2 C3O–Zn2 N4–Zn2
1X8I CphA
(B2)a
1.9 Biapenem [61] 2.7 2.8 4.0 3.4 – 2.4 2.2
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catalysis is supported by the very weak activities of the H118A
and H196A mutants [63]. Hence, B2 enzymes can bind a second
Zn(II) ion at a modified M1 site, giving rise though to an inactive
form since the metal at this site is not capable of fulfilling the role
of Zn1 in B1 and B3 enzymes. The structure of di-Zn(II) CphA
indeed suggests that Asn in position 116 precludes properly posi-
tioning of the Zn1 ion to activate the nucleophilic water molecule,
and sequesters residues His 118 and His 196 impeding their partic-
ipation in the catalytic mechanism as seen in the active mono-
nuclear form of B2 enzymes.
3. Crystal structures with hydrolyzed substrates
3.1. Crystal structure of NDM-1 in complex with various hydrolyzed
penicillins and hydrolyzed meropenem
The crystal structure of the B1 enzyme NDM-1 was solved in
complex with several hydrolyzed penicillins: ampicillin [59],
methicillin, benzylpenicillin, and oxacillin [44]. These structures
feature some important similarities: all of them present a water/
hydroxide molecule bridging both Zn(II) ions, with a longer
Zn1–Zn2 distance than in the resting state, always with a weaker
interaction with Zn2 (Table 2 and Fig. 4D). The complexes with
hydrolyzed penicillins present the longest distances (4.6 Å)
reported for a dinuclear MBL (Table 1).
The R1 functional groups display variable conformations, while
the orientation of the b-lactam core is identical in all the product
complexes. The hydrolyzed antibiotics contain two carboxylate
groups: the conserved C3-carboxylate, and the C7-carboxylate
(this one is generated after hydrolysis of the amide bond). The
C3-carboxylate coordinates Zn2 and forms a salt bridge withLys224. The nitrogen atom of the b-lactam ring (N4) is positioned
on top of Zn2 at a bonding distance of 2.2 Å (Table 2 and Fig. 4D).
The interaction of Zn2 with these two moieties is present in all
enzyme–product complexes and is in agreement with the pro-
posed substrate binding mode and reaction intermediates. One of
the oxygen atoms of the C7 carboxylate is bound to Zn1, while
the other oxygen is involved in a hydrogen bond interaction with
Asn233, conserved among B1 and B2 enzymes [39]. The bulky R1
groups of methicillin and oxacillin are accommodated on the active
site cleft, between the L3- and L10-loops, which is enlarged with
respect to other B1 MBLs [44].
The complex of NDM with hydrolyzed meropenem, instead,
reveals a somehow different scenario [44]. The direct coordination
of the carbapenem C3 carboxylate and the N4 atom with the Zn2
ion are preserved (Table 2), while the major difference resides in
the position of the newly formed C7 carboxylate. This moiety is
found bridging the two Zn(II) ions (at 2.2 and 2.6 Å from Zn1 and
Zn2, respectively), giving rise to a tetrahedral Zn1 site and a
hexa-coordinate Zn2 site in the product complex. As a result, there
is no water/hydroxide in this position and the Zn1–Zn2 distance is
shorter than in the other complexes, but still larger than in the
resting form (4.0 Å, see Table 2). Another structure deposited by
Kim et al. (PDB 4RBS) of NDM-1 in complex with meropenem
shows a very similar disposition (see Table 2).
A common feature of these structures is that Wat2, binding Zn2
in the resting form, is replaced in the enzyme–product adducts by
the interactions with the carboxylate and the nitrogen atom,
expanding the coordination sphere of Zn2 and reflecting the ability
of this site to bind negatively charged moieties. The presence of a
water/hydroxide bridging the two Zn(II) ions after the nucleophilic
attack [44,59] reflects the uptake of a new solvent molecule or the
rearrangement of Wat2 into this position, as suggested in the pro-
Fig. 4. Active sites of free, EI and EP adducts solved by crystallography. (A) Free form of NDM-1 (PDB 3SPU). (B) Free form of L1 (PDB 2FM6). (C) Free form of CphA (PDB 1X8G).
(D) NDM-1 in complex with hydrolyzed ampicillin (PDB 3Q6X) (E) L1 in complex with hydrolyzed moxolactam (PDB 2AIO). (F) CphA in complex with hydrolyzed biapenem
(PDB 1X8I). (G) NDM-1 in complex with hydrolyzed meropenem (4EYL). (H) Reaction mechanism for hydrolysis of cephalosporins with good R2 leaving groups (i.e.,
cefuroxime) by NDM-1 [79]. (I) NDM-1 in complex with a cefuroxime hydrolysis intermediate (4RLO) corresponding to species EI2 in panel H. W1 stands for Wat1 and W2
stands for Wat2.
3428 M.-R. Meini et al. / FEBS Letters 589 (2015) 3419–3432posed mechanisms (Figs. 1B and 2). This observation validates the
proposal that this water molecule is the proton donor. The lack of a
solvent molecule in the meropenem complex could be attributed
to a possible protonation on the carbon atom in the intermediatewithin the active site by an incoming water molecule from the
bulk. However, the electron density maps preclude assessing the
protonation state and hybridization of the carbon atom in these
adducts.
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cephalosporin and a cephalosporoate intermediate
The crystal structures of NDM-1 in complex with a cefuroxime
intermediate and hydrolyzed cephalexin were solved at 1.3 and
2.0 Å, respectively [79]. The two hydrolyzed cephalosporins in
complex with NDM-1 show very similar arrangements. In both
cases, the bridging water/hydroxide molecule is present between
the two Zn(II) ions (Fig. 4I). The newly formed carboxylate group
at C8 interacts with Zn1 and with Asn233. The nitrogen atom of
the opened b-lactam ring (N5) and the C4-carboxylate are bound
to Zn2, with the latter also interacting with Lys224. The major dif-
ference is the Zn1–Zn2 distance, which is shorter for the cefurox-
ime intermediate (3.8 Å) than for the complex with cephalexin
product (4.5 Å). Overall, the active site interactions resemble more
closely those found in the enzyme–product adducts of NDM-1 with
hydrolyzed penicillins than those with meropenem.
The hydrolysis of cephalosporins with good R2 leaving groups,
like cefalotin, ceftazidime and cefoxitin, proceeds through: (i) tau-
tomerization of the double bond in the dihydrothiazine ring from
position 3–4 to 4–5 and (ii) protonation and elimination of the
R2 group with formation of a new double bond 3–30 (Fig. 4H). This
was demonstrated to be the case for cefuroxime, which presents a
carbamoyl R2 group [79]. Surprisingly, in the structure of NDM-1
in complex with cefuroxime there was density for the carbamoyl
group, suggesting that an intermediate step was captured
(Fig. 4I). The planarity among C6, N5, C4 and C16 indicates a shifted
double bond from position 3–4 to 4–5 (Fig. 4H). Also, C3 shows sp3
hybridization, suggesting a transition from sp2 in the substrate to
sp3 in the trapped species, and a double bond rearrangement. Feng
et al. modeled an intermediate containing a negatively charged C3
with perfect density fitting. This anionic intermediate resembles
the one proposed for nitrocefin [66] and imipenem [23] hydrolysis.
In the case of nitrocefin, though the intermediate has been
described as negatively charged on N5 atom [66], it is stabilized
by delocalization through an extended p-conjugated system that
includes the C3 and C4 atoms and the dinitrostyryl group of the
R2 substituent [121]. In the case of the model proposed for imipe-
nem, it would be equivalent to EI2, in which the negative charge is
localized at C3. At the same time, this intermediate strongly sup-
ports the proposal that the C–N bond cleavage and nitrogen proto-
nation proceed in two separate steps, and that this last step is the
rate-limiting one.
In the case of the cephalexin complex, the ligand electron den-
sity accommodates a hydrolyzed molecule displaying a C3 with sp3
hybridization, suggesting full protonation of C3. Cephalexin lacks a
good leaving group and therefore hydrolysis proceeds through a
proton uptake at position 3.
3.3. L1 with hydrolyzed moxalactam
The crystal structure of L1 with the hydrolyzed form of the oxa-
cephem antibiotic moxalactam was the first one of a di-Zn(II) MBL
in complex with a hydrolyzed substrate [60]. Hydrolyzed moxalac-
tam binds the enzyme through interactions with both Zn(II) ions
and with side chains of residues adjacent to the active site
(Fig. 4E). Zn2 binds the b-lactam amide nitrogen and the C4 car-
boxylate, replicating the already reported features, while Zn1
interacts with the carboxylate group generated after hydrolysis
of the b-lactam. The C4 carboxylate also interacts with Ser221
and Ser223, functionally equivalent to the Lys224 residue present
in B1 and B2 MBLs [44,75,122], despite not being essential for
catalysis [110].
The C8 carboxylate generated after b-lactam hydrolysis is a Zn1
ligand, which becomes penta-coordinate with a distorted trigonal
bipyramidal geometry. The carboxylate at position C4 of the mox-alactam displaces the ‘‘apical” water molecule (Wat2) present in
the Zn2 coordination sphere in the resting enzyme while the
b-lactam nitrogen atom (N5) approaches from a direction opposite
to His121. This arrangement supports a role for Zn2 in stabilizing
the transient development of a negative charge on the N5 nitrogen
atom. In addition, the structure shows a water/hydroxide molecule
bridging the two metal ions, in line with the complexes of NDM-1
with hydrolyzed penicillins and cephalosporins.
3.4. CphA crystal structure in complex with hydrolyzed biapenem
Soaking of CphA crystals with biapenem allowed trapping of a
bound species in the active site, resulting from a molecular rear-
rangement in the substrate after the nucleophilic attack [61]. As
observed in the previously discussed adducts, the C–N b-lactam
bond has already been cleaved, the N4 atom and the C3 carboxy-
late bind the Zn(II) ion, and the latter also interacts with Lys224
and with the backbone nitrogen atom of Asn233 (Table 2 and
Fig. 4F). The molecule has lost the double bond C2@C3 and has
undergone an internal molecular rearrangement, with several
hydrophobic contacts within the active site pocket.
A water molecule (Wat1) is located at 2.9 Å of the N4 of the
intermediate and at 2.7 Å of His118, suggesting that the interaction
with His118 can reduce the pKa of Wat1 sufficiently for it to act as
the nucleophile or to transfer a proton to the intermediate (Fig. 3).
This interaction however is not as tight as the one reported for
resting Sfh-I, that confirms this hypothesis (see Tables 1 and 2).
This structure is in line with the previously discussed mechanisms,
and the observed rearrangement can be attributed to the unique
nature of this substrate.4. Concluding remarks
The main difficulties to design inhibitors for MBLs have resided
in the considerable structural differences among the active site of
enzymes from the different subclasses, and the distinct require-
ments of Zn(II) ions for the activity. This review aims to cover in
an integrated form, the different mechanistic and structural stud-
ies on MBLs from the three subclasses, B1, B2 and B3.
One of the most striking differences in the proposed mecha-
nisms is the activation of the attacking nucleophile. Dinuclear B1
and B3 enzymes use Zn1 as a Lewis acid to generate a nucleophilic
hydroxide in the active site, as reported for most Zn(II)-dependent
hydrolases. In contrast, mono-Zn(II) B2 do not employ the metal
ion for this purpose, but instead, rely on a hydrogen bond network
in the active site. His118 and His196 are thus involved in nucle-
ophile activation in all enzymes, either by coordinating Zn1 in din-
uclear enzymes or by direct interaction with the nucleophile in
mononuclear enzymes. The latter case applies as well to the native
mono-Zn(II) B2 enzymes or to B1 and B3 in the mono-Zn2 form.
MBLs use these essential residues in a modular form, in which
the putative M1 site activates the nucleophile, in such a way that
substrate binding and orientation is not expected to differ consid-
erably among class B enzymes. As a consequence, the presence of a
metal ion at the M1 site is not essential for hydrolysis in all MBLs,
since the role of Zn1 in dinuclear enzymes (activation of the nucle-
ophilic water molecule) can be fulfilled by a particular set and
arrangement of residues in mononuclear B2 enzymes and in the
mononuclear B3 enzyme GOB. It is still a matter of debate whether
the mono-Zn1 MBLs are biologically relevant. In any case, the
metal in the M1 site becomes essential for hydrolysis of
b-lactams in this mononuclear form of some B1 and B3 enzymes,
being responsible for nucleophile activation and for the protona-
tion step. The ligands of the now empty M2 site participate in a
hydrogen-bond network to orient the nucleophile and to guide
3430 M.-R. Meini et al. / FEBS Letters 589 (2015) 3419–3432the second catalytic water molecule to the zinc ion after the sub-
strate is bound. However, the finding that B1 enzymes are only
active in the periplasm as di-Zn(II) enzymes questions whether
in vitro studies on mono-Zn(II) enzymes could be translated to
the in vivo active species.
The role and essentiality of Zn2 is preserved for all MBLs and
against all types of b-lactam substrates (cf. Figs. 1–3). Zn2 provides
the main electrostatic anchoring for substrate binding, which can
be aided by different positively charged or polar residues varying
along the MBL family. Mechanistic, mutagenesis and crystallo-
graphic information also support the role of Zn2 in stabilizing a
common anionic reaction intermediate, in which the C–N
b-lactam bond has already been cleaved. The differences observed
with the distinct substrates, penicillins, cephalosporins and
carbapenems are due to their particular structure that impact dif-
ferentially in the accumulation of this anionic species. In any case,
these evidences point to common mechanistic features in all MBLs,
regardless the disparate structures of the distinct b-lactam
substrates and active sites.
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